PARADIGM-HF
PARADIGM-HF is the largest study to date in heart failure patients. 1Summary:
The PARADIGM-HF study on systolic heart failure with 8,399 patients in NYHA class II-IV. 2,3...
Twitter Linkedin Facebook Pinterest Google plusDosing
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Twitter Linkedin Facebook Pinterest Google plusMechanism of Action
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Twitter Linkedin Facebook Pinterest Google plusTraining/Video
MPN10 - Symptoomzoeker
Download Dutch documentMPN10 - Connaissez votre score
Download French documentHighlights From ASCO 2022
Ribociclib Breast Cancer Presentations
MONALEESA-2 OS BY DOSE REDUCTION poster discussion | Hart LL In this exploratory analysis of ML-2, 1L RIB + LET maintained OS benefit in postmenopausal pts with HR+, HER2...Twitter Linkedin Facebook Pinterest Google plusIndication
KISQALI is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as...
Twitter Linkedin Facebook Pinterest Google plusIndications
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Twitter Linkedin Facebook Pinterest Google plus
×